Biotechnology in China – regulation, investment, and delayed commercialization
China
May 16, 2022
China has been investing heavily in biotechnology to increase agricultural productivity. While a number of Chinese developed GM crops have cleared the required scientific hurdles – some more than a decade ago – commercialization has not been approved. The regulatory regime for GMOs in China is relatively less well understood than that of the US or the EU. This paper provides a systematic overview of China’s regulatory regime, R&D investment and delayed commercialization decisions on biotechnology over the last 40 years and draws some conclusions regarding the likelihood of the commercialization for major GM crops in the future.
AMS Publishes Final Rule for Updates to the List of Bioengineered
USA
Nov 30, 2023
Chapter 14 - Regulatory overview of genome-edited plants in Asian countries
China
Nov 29, 2023
EU - Regulatory aspects of plants resulting from new genomic techniques in the European Union
European Union
Nov 28, 2023
Revisiting the legal debate on Genetically Modified Organisms (GMOs) in Africa: Which way for Kenya?
Kenya
Nov 20, 2023
MFDS proposes safety review of GM foods by 2023
South Korea
Oct 30, 2023
EU Commission - New GMO approvals and authorisation renewals
European Union
Oct 20, 2023
FSAZN calls for submission on processing aid, new ingredients and GMOs
Australia
Oct 20, 2023
MARA consults on new GMOs labeling rules
China
Oct 16, 2023
Proposal for a Regulation on plants from New Genomic Techniques
Ireland
Sep 07, 2023
Parliament strengthens control over GMO production
Ukraine
Sep 04, 2023
FSANZ calls for comments on new GMO corn
Australia
Aug 09, 2023
EU Commission - New GMO approvals and authorisation renewals
European Union
Jul 05, 2023
New online system for application of regulated products
UK
Jun 26, 2023
The legal aspect of the current use of genetically modified organisms in Kenya, Tanzania, and Uganda
Kenya
May 15, 2023
Draft Resolution on Genetically Modified Foods published
Panama
Apr 28, 2023
